What project was biomy selected for?

The 'Post-5G Information and Communication Systems Infrastructure Enhancement R&D Project / Development of Competitive Generative AI Foundation Models (GENIAC)' promoted by METI and NEDO.

Who is collaborating on this project?

biomy will collaborate with the Cancer Institute Hospital of JFCR, the University of Tokyo, and the Japan Biological Informatics Consortium (JBIC).

Why develop the Virtual Cell foundation model?

To overcome the difficulty of predicting drug efficacy in complex tumor microenvironments, aiming to shorten drug development periods and improve clinical trial success rates.

When did the GENIAC project begin?

The project started in February 2024, and this is the 4th round of selections.

Where and how will the developed model be utilized?

It will be validated with JBIC through industry-academia-government collaboration, and after demonstration, non-exclusive licenses will be provided to contribute to next-generation AI drug discovery.

AI News NQ Analysis

biomy Selected for METI/NEDO GENIAC Program for Generative AI Foundation Model

NQ Score 86/100

N1 Content Completeness 85

AI Summary (NQ-processed)

biomy has been selected for the GENIAC project by METI and NEDO. Partnering with the Cancer Institute and UTokyo, it will develop the 'Virtual Cell' multimodal spatial AI model to accelerate next-gen drug discovery.

AI Analysis

Frequently Asked Questions

Q: What project was biomy selected for?: A: The 'Post-5G Information and Communication Systems Infrastructure Enhancement R&D Project / Development of Competitive Generative AI Foundation Models (GENIAC)' promoted by METI and NEDO.
Q: Who is collaborating on this project?: A: biomy will collaborate with the Cancer Institute Hospital of JFCR, the University of Tokyo, and the Japan Biological Informatics Consortium (JBIC).
Q: Why develop the Virtual Cell foundation model?: A: To overcome the difficulty of predicting drug efficacy in complex tumor microenvironments, aiming to shorten drug development periods and improve clinical trial success rates.
Q: When did the GENIAC project begin?: A: The project started in February 2024, and this is the 4th round of selections.
Q: Where and how will the developed model be utilized?: A: It will be validated with JBIC through industry-academia-government collaboration, and after demonstration, non-exclusive licenses will be provided to contribute to next-generation AI drug discovery.